Angiotensin receptor blockers and cardiovascular outcomes

BMJ

Volumn 342, Issue 7805, 2011, Pages

  Richard, F D ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DROSPIRENONE; GENERIC DRUG; LEVONORGESTREL; PLACEBO; PROTON PUMP INHIBITOR; ROFECOXIB; VALDECOXIB; VALSARTAN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DRUG SAFETY; EDITORIAL; HEART FAILURE; HEART INFARCTION; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; PRESCRIPTION; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SYSTEMATIC REVIEW (TOPIC); TERMINAL DISEASE; CHEMICALLY INDUCED DISORDER; HUMAN; NOTE; RISK FACTOR;

ANGIOTENSIN RECEPTOR ANTAGONISTS; HUMANS; MYOCARDIAL INFARCTION; RISK FACTORS;

EID: 79955649225     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d2193     Document Type: Editorial

References (10)

1. Bangalore S, Kumar S, Wetterslev J, Messerli FH. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 2011;342:d2234.
2. Sun SX, Lee KY, Bertram CT, Goldstein JL. Withdrawal of cox-2 inhibitors rofecoxib and valdecoxib: impact on NSAID and PPI prescriptions and expenditures. Curr Med Res Opin 2007;8:1859-66. (Pubitemid 47300385)
3. Drife JO. The third generation pill controversy ("continued"): the risks are still small compared with those of pregnancy. BMJ 2001;323:119-20. (Pubitemid 32678377)
4. Dunn N. The risk of deep venous thrombosis with oral contraceptives containing drospirenone. BMJ 2011;342:d2519.
5. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al; VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31.
6. Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ 2004;329:1248-9. (Pubitemid 39582781)
7. Turnbull F, Neal B, Algert C, Chalmers J, Woodward M, MacMahon S. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35. (Pubitemid 37410190)
8. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000;356:1955-64.
9. Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008;148:16-29. (Pubitemid 351664943)
10. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369:201-7. (Pubitemid 46111014)